Biblio
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase . Lancet Haematol. 2022;9(11):e810-e821.
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nat Cancer. 2022.
Collection, cryostorage, transplantation and disposal of hematopoietic stem cell products. Biol Blood Marrow Transplant. 2018.
. Cyclophosphamide etoposide dexamethasone (CED) as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma. Hematol Oncol. 2023.
. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur J Immunol. 2021;51(12):2708-3145.
Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. Transplant Cell Ther. 2021.
Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD. Trials. 2023;24(1):591.
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer. 2023;23(1):1132.
. Storage, Utilization and Disposal of Hematopoietic Stem Cell Products in Multiple Myeloma Patients. Biol Blood Marrow Transplant. 2020.